ArticleESMO open2026

Cost-effectiveness of switching to S-1 after fluoropyrimidine-induced hand-foot syndrome or cardiovascular toxicity in the treatment of metastatic colorectal cancer.

R van Eekelen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.